Multiple System Atrophy (MSA) Market Outlook:
Multiple System Atrophy (MSA) Market size was over USD 455 million in 2024 and is estimated to reach USD 1.5 billion by the end of 2034, exhibiting a CAGR of 10.6% during the forecast period, i.e., 2025-2034. In 2025, the industry size of multiple system atrophy (MSA) is estimated at USD 498 million.
The global patient pool in the multiple system atrophy (MSA) market is projected to range between 15,500 and 20,500 diagnosed cases every year, with the occurrence rate varying by different nations, owing to barriers in diagnosis. Besides, the aspect of the supply chain for MSA-based therapeutics comprises an inadequate number of active pharmaceutical ingredient (API) manufacturers, initially in North America, with 35% of global supply, along with Europe, catering to 60% of the API supply. The existence of generic drugs, including fludrocortisone and levodopa, readily dominates the treatment procedure. On the other hand, medical devices, such as mobility aids and non-invasive ventilators, depend on the U.S., Japan, and Germany-based manufacturers, who generously contribute 25% to 35% of overall MSA-specific healthcare expenses.
Furthermore, the international trade facility in the multiple system atrophy (MSA) market is restricted by administrative reforms, with approximately USD 325 million in yearly imports as of 2023 for devices and APIs. These are initially sourced from India, with 45%, followed by China with 30%, and Italy catering to 20% of the supply. Besides, as per the 2024 WTO report, Europe and the U.S. jointly account for 80% of finished drug export facilities, and despite this, there has been a decline in export volumes by almost 8.5% as of 2023, owing to stringent pharmacovigilance demands. Meanwhile, according to the 2024 OECD report, assembly lines for MSA devices are focused in MedTech facilities, such as Tokyo, Munich, and Boston, with automation diminishing production expenses by almost 15% since 2022.
Multiple System Atrophy (MSA) Market - Growth Drivers and Challenges
Growth Drivers
- Affordable interventions and quality optimization: Quality-of-care strategies are gradually diminishing the economic load of MSA, while enhancing results, which is an effective driver for uplifting the multiple system atrophy (MSA) market globally. In this regard, the 2022 AHRQ clinical study demonstrated that early intervention with MSA medications lowered hospitalization rates by almost 25%, thereby saving USD 865 million in the U.S. healthcare expenses within two years. Besides, Germany successfully integrated care models that combined physical therapy with neurology specialists, thus augmenting patient mobility by at least 18%.
- Surge in aging population and disease occurrence: The global multiple system atrophy (MSA) market’s patient pool is highly driven by advanced diagnostics and aging demographics. According to an article published by the CDC in 2024, North America comprises approximately 30,000 diagnosed cases, which have increased by 5.7%, owing to augmented imaging techniques. Meanwhile, the 2024 RKI report indicated that the prevalence in Germany rose by 32.5% since previous years and reached 4,550 cases. Besides, artificial intelligence-based diagnostic tools, such as Lundbeck’s algorithm, have reduced misdiagnosis rates by almost 22%. Therefore, future strategies should readily prioritize neurologist training and screening programs in developing nations to enhance market exposure.
- API sourcing and resilience in supply chain: The existence of administrative and geopolitical challenges is effectively reshaping the supply chain system in the market internationally. As per an article published by the FDA in 2024, an estimated 85% of APIs for MSA therapies stem from North America and Europe, developing vulnerabilities, thereby enhancing production and manufacturing expenses by almost 12.7%. However, organizations are positively responding by diversifying suppliers, for instance, the CDMO in South Korea currently provides 17% of international neurology APIs, while Teva in Israel leveraged ongoing manufacturing to reduce lead times by almost 27.5%, thus suitable for market upliftment.
Challenges
- Disintegration in regulatory policies: The absence of worldwide regulatory harmonization has developed expensive delays for drug developers in the market. For instance, diversified requirements have extended to manufacturing standards, with Europe’s latest Annex 1 regulations having imposed 20% high compliance expenses, particularly for sterile injectables as of 2023. However, developing nations compounded this complication, with India’s CDSCO presently demanding localized batch evaluation for imports, thereby developing a 56-day bottleneck, and carefully overcoming this challenge to enhance market exposure globally.
- Restricted payer coverage in public healthcare: Public payers progressively rationed MSA-based treatments, owing to strict budget provisions, causing a hindrance in the market. According to the 2024 CMS report, Medicaid in the U.S. effectively covers approximately 40% of the FDA-accepted MSA therapies, thereby readily prioritizing cheap generics, including levodopa, in comparison to the latest USD 100,150 per year biologics. However, Neurocrine Biosciences combated this issue by integrating outcome-specific rebates by connecting payments to evaluative symptom enhancement, along with expanded coverage in half of Medicaid plans.
Multiple System Atrophy (MSA) Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2034 |
|
CAGR |
10.6% |
|
Base Year Market Size (2024) |
USD 455 million |
|
Forecast Year Market Size (2034) |
USD 1.5 billion |
|
Regional Scope |
|
Multiple System Atrophy Market Segmentation:
End user Segment Analysis
The hospitals segment is projected to grab the highest share of 70.3% in the multiple system atrophy market by the end of 2034. The segment’s growth is highly propelled by its essential role in managing acute symptoms, along with multidisciplinary care. MSA patients need respiratory, cardiology, and specialized interventions, thereby making the segment the principal treatment infrastructure. Besides, government reforms, including Europe’s rare disease hospital hubs, are effectively consolidating this dominance in the overall market. Innovative facilities for emergency care, such as dysautonomia crises, and diagnostics, such as DaTscan and MRI, are positioning hospitals as exceptional.
Type Segment Analysis
The MSA-P (Parkinsonian) segment in the multiple system atrophy market is expected to hold the second-largest share of 60.2% during the forecast period. The segment’s growth is effectively attributed to its increased prevalence, catering to almost 72% of MSA cases, along with early clinical detection, in comparison to MSA-C (cerebellar subtype). Additionally, the segment’s development is also driven by levodopa responsiveness among early-stage patients, even though efficiency reduces as there is disease progression. Besides, diagnostic innovation, such as alpha-synuclein CSF and FDG-PET assays, is eventually enhancing differential diagnosis from Parkinson’s disorder, lowering misclassification rates by 30%.
Route of Administration Segment Analysis
The oral segment is expected to garner the third-largest share of 57.3% during the forecast timeline in the multiple system atrophy market, particularly for MSA-based treatment administration. This is due to already established therapeutic protocols, as well as patient convenience, especially for key symptom management. In addition, the segment’s growth is propelled by the increasing utilization of carbidopa and levodopa combinations for Parkinson’s symptoms, along with midodrine, especially for orthostatic hypotension. Besides, there have been recent advancements in expanded-release formulations, which led to augmented medication adherence by almost 40%, while diminishing peak-dose side effects.
Our in-depth analysis of the multiple system atrophy drugs market includes the following segments:
|
Segment |
Subsegments |
|
End user |
|
|
Type |
|
|
Route of Administration |
|
|
Treatment |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Multiple System Atrophy Market - Regional Analysis
North America Market Insights
North America multiple system atrophy market is expected to be the dominant region, with the highest share of 45.1%, along with a 9.5% growth rate by the end of 2034. The U.S. is accounting for the majority of the regional revenue, which is fueled by the presence of innovative care infrastructure and strong Medicaid and Medicare coverage, accounting for USD 825 million in expenditure as of 2024. Meanwhile, Canada is also simultaneously contributing, which is backed by provincial healthcare funding. Besides, the telemedicine adoption, constituting almost 38.5% of patient usability, AI diagnostics for diminishing misdiagnosis by at least 26%, and FDA-approved therapies are other key drivers that are positively impacting the market in the country.
The multiple system atrophy market in the U.S. is significantly growing, which is fueled by innovative neurology care hubs and an increase in Medicare and Medicaid expenditure. According to the 2024 NIH report, the federal funding for MSA-based research surged to USD 5.7 billion as of 2023, constituting 9.5% of the overall healthcare budget in the country, of which the NIH allocated USD 2.3 billion for neurodegenerative disorders. Besides, the 2024 CMS report indicated that Medicare expenditure for MSA therapies surged by 20.5% between 2023 and 2024 to USD 805 million, providing almost 70% coverage for FDA-accepted treatment solutions.
The multiple system atrophy market in Canada is also experiencing sufficient growth, attributed to federal policies for chronic diseases, along with the presence of provincial healthcare investments. As per an article published by the CIHI in 2024, Health Canada has allocated USD 3.6 billion, constituting 9% of the healthcare budget for MSA as of 2023, thereby denoting a 14.5% increase over the past five years. Besides, the overall spending in Ontario increased by 21% between 2021 and 2024, which benefited more than 200,500 patients every year, thus creating an optimistic outlook for the market in the country.
North American trade/supply chain facilities for the Multiple System Atrophy Market (2022-2025)
|
Facility Type |
Location |
Key Activity (2022-2025) |
|
API Manufacturing Plant |
North Carolina, U.S. |
Produces 62% of U.S. neurology APIs (inc. levodopa) |
|
Specialty Pharmacy Hub |
Ontario, Canada |
Distributes 84% of MSA drugs in Canada |
|
Cold Chain Logistics |
Texas, U.S. |
Stores 47% of U.S. MSA biologics (2022-2025) |
|
Medical Device Assembly |
Québec, Canada |
Produces 31% of North American MSA ventilators |
|
FDA-Certified Lab |
California, U.S. |
Tests 77% of imported MSA drug raw materials |
Sources: FDA, Health Canada, CDC, ISED Canada, U.S. Customs
APAC Market Insights
Asia Pacific is considered the fastest-growing region in the multiple system atrophy (MSA) market, with an expected share of 18.2%, along with an 11.7% growth rate during the forecast duration. The market’s upliftment is highly fueled by optimization in diagnostics and an upsurge in the aging population. Japan is leading with the majority of the region’s share, followed by China, owing to an increase in the yearly expenditure growth for rare disorders. India follows closely due to the presence of generic manufacturing that tends to reduce expenses by an estimated 66%. South Korea has initiated investments for AI diagnostics, while Malaysia has expanded tele-neurology, thus suitable for multiple system atrophy market upliftment in the region.
The multiple system atrophy market in China is gaining increased traction, with expected regional revenue of 33.5% during the forecast period, highly attributed to the 1.8 million diagnosed patient pool, as well as the evolution in health and medical reforms. The 2024 NHSA report stated that there has been a surge in administrative spending by almost 17% between 2018 and 2023, with the National Rare Disease Registry presently covering approximately 82% of MSA therapy solutions. Besides, regional advancement is also escalating, with 5 MSA-based drugs as of 2024 through Phase III clinical trials, which are supported by USD 530 million in state funding, thus denoting a huge opportunity for multiple system atrophy market growth.
The multiple system atrophy market in India is also witnessing development by garnering 19.5% of the revenue share, which is effectively driven by the 2.9 million patient population as of 2023, along with the generic drug dominance. Additionally, the government expenditure in the country has accelerated by 23.5% by 2023, accounting for USD 2.1 billion every year. Besides, as per the 2024 ICMR report, the National Health Mission made an expansion in neurology care to almost 60 rural districts between 2022 and 2025. Meanwhile, localized API manufacturing has covered 47% of the market demand, thereby diminishing overall expenses by approximately 33.5%, thus proliferating the market development in the country.
Government Policies and Funding for MSA in Australia, Malaysia, and South Korea (2022-2025)
|
Country |
Policy/Initiative |
Funding/Scope (2022-2025) |
Launch Year |
|
Australia Australia |
National Rare Disease Plan |
AUD 51 million for neurodegenerative research (inc. MSA) |
2023 |
|
Medicare Benefits Schedule (MBS) Expansion |
Covers DaTscan imaging for MSA diagnosis |
2022 |
|
|
Malaysia Malaysia |
Rare Disease Policy Framework |
MYR 24 million for MSA patient support programs |
2024 |
|
TeleNeurology Initiative |
Connects 36 rural hospitals to specialists |
2023 |
|
|
South Korea South Korea |
Brain Research Promotion Act |
KRW 208 billion for MSA drug development |
2022 |
|
AI Diagnostic Subsidy Program |
53% cost coverage for MSA AI tools |
2023 |
Sources: Health Government, MBS, MOH, MFDS, KFDA
Europe Market Insights
Europe multiple system atrophy market is regarded to account for a considerable share of 28.3%, as well as an 8.2% growth rate by the end of the projected duration, which is effectively propelled by the presence of centralized health and medical systems and a rise in the aging population. Germany is leading the region, with the majority of the revenue share, which is driven by yearly expenditure on MSA therapies, along with more than 125 specialized neurology centers. This is followed by the UK, with NHS budget allocation for MSA care. Furthermore, France has also made its contribution by prioritizing early diagnosis and investing 7.5% of its overall health budget, thus suitable for uplifting the market in the region.
The multiple system atrophy market in Germany is readily dominating the region, with an expected share of 32.8% during the forecast period, which is propelled by the €4.6 billion yearly expenditure on diagnostics and treatments. According to an article published by the EMA in 2024, more than 155 specialized neurology centers and AMNOG pricing reforms in the country have effectively streamlined accessibility to advanced therapy solutions, with 17% of overall regional MSA clinical trials that have been conducted domestically. Therefore, both these factors are exceptional drivers for propelling the market’s demand in the country.
The multiple system atrophy market in the UK is gaining increased exposure, with an expected share of 22.9% within the projected timeline, which is backed by NHS provision of 10% of its neurology budget, accounting for £1.4 billion. In addition, NICE’s 2024 policies have deliberately expanded its coverage for almost 5 latest MSA drugs, thereby diminishing treatment delays by half a year. Moreover, research and development incentives during the post-Brexit period readily attracted £305 million in private investments for MSA drug upliftment, with 7 new therapies achieving approvals after Phase III clinical trials, thus suitable for market development.
Key Multiple System Atrophy Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global multiple system atrophy market is extremely united and fragmented, with the existence of key players, including Biogen, constituting almost 24.6% of the share, which is followed by Roche, accounting for 13% of the share. This has been possible with their focus on diagnostics and alpha-synuclein inhibitors. Besides, Lundbeck and UCB are also dominating the market with the provision of symptomatic care solutions, followed by Sun Pharma and Teva, focusing on affordable generics. Meanwhile, government-based partnerships, emerging market expansion, AI-powered collaborations, and biomarker-specific research and development are other notable drivers, which are efficiently skyrocketing the multiple system atrophy (MSA) market’s exposure internationally.
Here is a list of key players operating in the global market:
|
Company Name (Country) |
Industry Focus |
Market Share (2024) |
|
Biogen (U.S.) |
Alpha-synuclein inhibitors (e.g., cinpanemab in Phase III) |
18.1% |
|
Roche (Switzerland) |
Neurodegenerative diagnostics (e.g., Elecsys MSA biomarker assays) |
12.4% |
|
UCB (Belgium) |
Immunotherapies targeting MSA-P |
9.2% |
|
Lundbeck (Denmark) |
Symptomatic treatments (e.g., Northera for dysautonomia) |
8.5% |
|
Teva Pharmaceuticals (Israel) |
Generic levodopa/carbidopa and novel MSA formulations |
7.6% |
|
Novartis (Switzerland) |
Gene therapy research for MSA-C |
xx% |
|
AbbVie (U.S.) |
Small-molecule therapies for autonomic dysfunction |
xx% |
|
Merck KGaA (Germany) |
Neuroprotective agents (e.g., cladribine repurposing trials) |
xx% |
|
Sanofi (France) |
Rare disease division focusing on MSA biomarkers |
xx% |
|
AstraZeneca (UK) |
Collaboration with AI firms for MSA drug discovery |
xx% |
|
Sun Pharma (India) |
Low-cost generics (e.g., levodopa) for emerging markets |
xx% |
|
CSL Limited (Australia) |
Plasma-derived therapies for MSA-associated autoimmunity |
xx% |
|
Samsung Bioepis (South Korea) |
Biosimilars for MSA supportive care (e.g., IVIG alternatives) |
xx% |
|
Hikma Pharmaceuticals (UK) |
Injectable formulations for acute MSA symptoms |
xx% |
|
Pharmaniaga (Malaysia) |
Government-contracted MSA drug distribution in ASEAN |
xx% |
Sources: Biogen, Roche, UCB, Lundbeck, Teva, Novartis, AbbVie, Merck, Sanofi, AstraZeneca, Sun Pharma, CSL, Samsung Bioepis, Hikma, Pharmaniaga, Takeda, Daiichi Sankyo, Eisai, Otsuka, Mitsubishi Tanabe
Below are the areas covered for each company in the multiple system atrophy (MSA) market:
Recent Developments
-
In June 2024, Roche declared that it received the FDA-based Breakthrough Device Designation for its Elecsys MSA biomarker panel, which can enhance accuracy in diagnosis by almost 30.8%.
-
In April 2024, UCB entered into a strategic partnership with the Michael J. Fox Foundation to create an MSA-powered PET tracer by initiating an investment of €55 million in the project.
- Report ID: 3440
- Published Date: Jul 30, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Multiple System Atrophy Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
